<DOC>
	<DOC>NCT01269021</DOC>
	<brief_summary>In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid . Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.</brief_summary>
	<brief_title>An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)</brief_title>
	<detailed_description>To access the efficacy and safety of MMF compared to corticosteroid in in treatment of proliferative IgA Nephropathy(IgAN).</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1. Patients who signed written informed consent form 2. age between 1860 years, female or male 3. diagnosed IgA Nephropathy (IgAN) by renal biopsy during 1 months 4. renal biopsy had: 10%&lt; crescents&lt;50%; endocapillary hypercellularity; or necrosis ,and interstitial fibrosis&lt;50%, 5. proteinuria&gt;1g/24h for two times 1. secondary IgA Nephropathy (IgAN); 2. eGFR&lt;30ml/min/1.73m2.( MDRD formula) 3. liver disfunction; 4. uncontrolled hypertension 5. WBC &lt;3000/mm3 6. Severe viral infection(HBV, HCV, CMV) within 3 months ofor known HIV infection. 7. diabetes or obesity(BMI&gt;28) ; 8. severe infection or central nervous system symptoms.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MMF treatment IgA Nephropathy (IgAN)</keyword>
</DOC>